| Bioactivity | UBP 302 is a potent and selective GLUK5-subunit containing kainate receptor antagonist (apparent Kd=402 nM), and displays very little affinity on GluK2 (GluR6) kainate receptors. Anxiolytic effects[1][2][3]. | ||||||||||||
| Target | apparent Kd: 402 nM (GLUK5)IC50: 106 μM (AMPA receptors) | ||||||||||||
| Name | UBP 302 | ||||||||||||
| CAS | 745055-91-8 | ||||||||||||
| Formula | C15H15N3O6 | ||||||||||||
| Molar Mass | 333.30 | ||||||||||||
| Appearance | Solid | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
||||||||||||
| Reference | [1]. More JC, et al. Characterisation of UBP296: a novel, potent and selective kainate receptor antagonist. Neuropharmacology. 2004 Jul;47(1):46-64. [2]. Dolman NP, et al. Synthesis and pharmacology of willardiine derivatives acting as antagonists of kainate receptors. J Med Chem. 2005 Dec 1;48(24):7867-81. [3]. Apland JP, et al. The limitations of diazepam as a treatment for nerve agent-induced seizures and neuropathology in rats: comparison with UBP302. J Pharmacol Exp Ther. 2014 Nov;351(2):359-72. |